TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20594588

Group type: EXPERIMENTAL
Intervention: Intensive glycaemia control (target HbA(1c) <6.0%)
Number of subjects: 10251

Group type: COMPARATOR
Intervention: Standard glycaemia control (target HbA(1c) 7.0-7.9%)
Number of subjects: 10251

Group type: EXPERIMENTAL
Intervention: Secondary measures favoring intensive therapy
Number of subjects: 10251
Study: 18854722

Group type: EXPERIMENTAL
Intervention: Fluoxetine (20-60 mg by mouth per day)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 16269081

Group type: EXPERIMENTAL
Intervention: ANCOVA
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mann‐Whitney
Number of subjects: 0
Study: 12242602

Group type: EXPERIMENTAL
Intervention: Mirtazapine (15 mg for 2 days, then 30 mg for 5 days) plus phenytoin (200 mg daily for 17 days)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Phenytoin (200 mg daily from day 8 to day 17) plus mirtazapine (15 mg for 2 days, then 30 mg for 15 days)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Phenytoin (200 mg daily)
Number of subjects: 17
Study: 10080828

Group type: EXPERIMENTAL
Intervention: rhIFN-gamma injections paired with PG
Number of subjects: 31

Group type: COMPARATOR
Intervention: normal saline injections paired with PG
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: rhIFN-gamma injections alone
Number of subjects: 31
Study: 7653318

Group type: COMPARATOR
Intervention: 2 mg nicotine gum (0 pieces per day)
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: 2 mg nicotine gum (7 pieces per day)
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: 2 mg nicotine gum (15 pieces per day)
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: 2 mg nicotine gum (30 pieces per day)
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: Salivary cotinine levels (high and low)
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: Withdrawal symptoms
Number of subjects: 177
Study: 2344503

Group type: EXPERIMENTAL
Intervention: Bendrofluazide 1.25 mg
Number of subjects: 257

Group type: EXPERIMENTAL
Intervention: Bendrofluazide 2.5 mg
Number of subjects: 257

Group type: EXPERIMENTAL
Intervention: Bendrofluazide 5 mg
Number of subjects: 257

Group type: EXPERIMENTAL
Intervention: Bendrofluazide 10 mg
Number of subjects: 257

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 257
Study: 344341

Group type: EXPERIMENTAL
Intervention: Immunofluorescence‐nDNA antibody test system
Number of subjects: 236

Group type: COMPARATOR
Intervention: Radioimmunoassay procedure (FARR assay)
Number of subjects: 236
Study: 30475668

Group type: EXPERIMENTAL
Intervention: Letrozole
Number of subjects: 8010

Group type: COMPARATOR
Intervention: Tamoxifen
Number of subjects: 8010
Study: 28934837

Group type: EXPERIMENTAL
Intervention: 1W bromocriptine treatment (2.5 mg for 7 days)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: 8W bromocriptine treatment (5 mg for 2 weeks followed by 2.5 mg for 6 weeks)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Control group (not treated with bromocriptine)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: 1W bromocriptine treatment
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: 8W bromocriptine treatment
Number of subjects: 63
Study: 25238025

Group type: EXPERIMENTAL
Intervention: Remogliflozin etabonate (RE) 100, 250, 500 or 1000 mg once daily or 250 mg twice daily
Number of subjects: 252

Group type: EXPERIMENTAL
Intervention: Remogliflozin etabonate (RE)
Number of subjects: 252

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 252

Group type: COMPARATOR
Intervention: 30 mg pioglitazone once daily
Number of subjects: 252
Study: 23169690

Group type: EXPERIMENTAL
Intervention: Mindfulness training
Number of subjects: 140

Group type: COMPARATOR
Intervention: Relaxation training
Number of subjects: 140
Study: 20878572

Group type: EXPERIMENTAL
Intervention: Paclitaxel combined with FOLFOX4 regimen neoadjuvant chemotherapy every two weeks in each cycle
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Paclitaxel combined with FOLFOX4 regimen neoadjuvant chemotherapy
Number of subjects: 78

Group type: COMPARATOR
Intervention: Control group received surgery within 2 weeks and postoperative chemotherapy of 6 cycles of paclitaxel combined with FOLFOX4 regimen
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 78
Study: 18436088

Group type: EXPERIMENTAL
Intervention: Educational intervention for family physicians (6 months duration)
Number of subjects: 94
Study: 16905888

Group type: EXPERIMENTAL
Intervention: Psychological training
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Physical activity training
Number of subjects: 118

Group type: COMPARATOR
Intervention: Both training groups
Number of subjects: 118
Study: 12802023

Group type: EXPERIMENTAL
Intervention: 17 alpha-hydroxyprogesterone caproate (17P) 250 mg weekly injections
Number of subjects: 463

Group type: COMPARATOR
Intervention: Placebo (inert oil) weekly injections
Number of subjects: 463
Study: 10844868

Group type: EXPERIMENTAL
Intervention: 1H‐MRS
Number of subjects: 14
Study: 8888419

Group type: EXPERIMENTAL
Intervention: Water exercise with X1000 Walk'N Tone Exercise Belt
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Land exercise with X1000 Walk'N Tone Exercise Belt
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Water exercise without X1000 Walk'N Tone Exercise Belt
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Land exercise without X1000 Walk'N Tone Exercise Belt
Number of subjects: 18
Study: 1891485

Group type: EXPERIMENTAL
Intervention: Alprazolam (1.48 mg daily)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Oxazepam (44.4 mg daily)
Number of subjects: 62
Study: 6576616

Group type: EXPERIMENTAL
Intervention: Short-term psychotherapy (one-hour weekly sessions for a maximum of ten sessions)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Medical treatment only (control group)
Number of subjects: 103
Study: 30198775

Group type: EXPERIMENTAL
Intervention: Intravenous iron isomaltoside (IVI)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 27
Study: 28453197

Group type: EXPERIMENTAL
Intervention: Peers present during the Iowa Gambling Task (IGT)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Alone during the Iowa Gambling Task (IGT)
Number of subjects: 101
Study: 24548816

Group type: EXPERIMENTAL
Intervention: Skin-to-skin contact (SSC) during diaper change
Number of subjects: 19

Group type: COMPARATOR
Intervention: Diaper change in incubator/bed with mother present
Number of subjects: 19
Study: 23222818

Group type: EXPERIMENTAL
Intervention: Prednisolone/Everolimus (P/EVL)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Prednisolone/Cyclosporine A (P/CsA)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Prednisolone/Mycophenolate Sodium (P/MPS)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Everolimus (mTOR inhibitor)
Number of subjects: 26
Study: 21615576

Group type: EXPERIMENTAL
Intervention: Pain education programme (experimental group)
Number of subjects: 122

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 122
Study: 17680591

Group type: EXPERIMENTAL
Intervention: Shapesville
Number of subjects: 84

Group type: COMPARATOR
Intervention: Control book
Number of subjects: 84
Study: 17157730

Group type: EXPERIMENTAL
Intervention: Mechanical shaving plus monopolar radiofrequency (MRF)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Mechanical shaving alone
Number of subjects: 60
Study: 14587684

Group type: EXPERIMENTAL
Intervention: Arnica D30
Number of subjects: 82

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study: 11025241

Group type: EXPERIMENTAL
Intervention: Sevoflurane-N2O
Number of subjects: 62

Group type: COMPARATOR
Intervention: Propofol for induction and isoflurane-N2O for maintenance (Control)
Number of subjects: 62
Study: 8988412

Group type: EXPERIMENTAL
Intervention: Azithromycin (AZM), 100 mg capsules or 10% fine granules, given orally
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Azithromycin (AZM), 8.3 mg/kg once daily for 3 days
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Azithromycin (AZM), 12.5 mg/kg once daily for 3 days
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Safety evaluation of Azithromycin (AZM)
Number of subjects: 27
Study: 1617930

Group type: EXPERIMENTAL
Intervention: roxithromycin (ROX) 150 mg b.i.d. orally (n = 244)
Number of subjects: 490

Group type: COMPARATOR
Intervention: amoxicillin plus clavulanic acid (AMX + CA) 500 mg AMX + 125 mg CA t.i.d. orally (n = 246)
Number of subjects: 490

Group type: COMPARATOR
Intervention: amoxicillin plus clavulanic acid (AMX + CA)
Number of subjects: 490

Group type: EXPERIMENTAL
Intervention: roxithromycin (ROX)
Number of subjects: 490
Study: 6398125

Group type: EXPERIMENTAL
Intervention: Fosfomycin plus amoxicillin (CFL)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Fosfomycin
Number of subjects: 73
Study: 30084900

Group type: EXPERIMENTAL
Intervention: SKN2017B
Number of subjects: 45

Group type: COMPARATOR
Intervention: Silicone cream
Number of subjects: 45
Study: 28988493

Group type: EXPERIMENTAL
Intervention: SMS text message feedback from a parent, peer, or behavioral health specialist
Number of subjects: 10

Group type: COMPARATOR
Intervention: No text message (control)
Number of subjects: 10
Study: 26308179

Group type: EXPERIMENTAL
Intervention: Carn‐BA (2 g of L‐carnosine and 2 g of β‐alanine)
Number of subjects: 12

Group type: COMPARATOR
Intervention: PLA (placebo)
Number of subjects: 12
Study: 24628890

Group type: EXPERIMENTAL
Intervention: Ex vivo lung perfusion (EVLP)
Number of subjects: 35
Study: 22684197

Group type: EXPERIMENTAL
Intervention: Dynamic Muscular Stabilization Technique (DMST)
Number of subjects: 72
Study: 19933530

Group type: EXPERIMENTAL
Intervention: Auscultation (AUS)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Lighted Stylet (LS)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Manufacturer‐Recommended (MR)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Fiberoptic Bronchoscope (FOB)
Number of subjects: 80
Study: 17870126

Group type: EXPERIMENTAL
Intervention: Core learning objectives curriculum
Number of subjects: 20

Group type: COMPARATOR
Intervention: Traditional curricula
Number of subjects: 20
Study: 16365694

Group type: EXPERIMENTAL
Intervention: MRI with closed mouth and 25 mm open mouth
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: MRI with closed mouth
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: MRI with 25 mm open mouth
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: MRI with 5 mm open mouth
Number of subjects: 16
Study: 12829905

Group type: EXPERIMENTAL
Intervention: Antibiotic prophylaxis for spontaneous bacterial peritonitis
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Posttransplant dialysis
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Retransplantation
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: C. albicans infections
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Cases (invasive candidiasis)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Non-albicans Candida infections
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Prior antifungal prophylaxis
Number of subjects: 35
Study: 11214766

Group type: EXPERIMENTAL
Intervention: tiopronin (200 mg/day) for 14 days
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: tiopronin (500 mg/day) for 14 days
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: bromocriptine (5 mg/day) for 14 days
Number of subjects: 100

Group type: COMPARATOR
Intervention: conservative measures (no medication)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: tiopronin (200 mg/day)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: tiopronin (500 mg/day)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: bromocriptine (5 mg/day)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: tiopronin (200 mg/day) and bromocriptine
Number of subjects: 100
Study: 8878196

Group type: EXPERIMENTAL
Intervention: Sub‐Tenon's anesthesia
Number of subjects: 106

Group type: COMPARATOR
Intervention: Retrobulbar anesthesia
Number of subjects: 106
Study: 1670746

Group type: EXPERIMENTAL
Intervention: Doxazosin (11.9 +/- 0.9 mg daily)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Doxazosin
Number of subjects: 73

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study: 6408068

Group type: EXPERIMENTAL
Intervention: Bupropion plus haloperidol
Number of subjects: 20

Group type: COMPARATOR
Intervention: Bupropion alone
Number of subjects: 20
Study: 31618617

Group type: EXPERIMENTAL
Intervention: Propensity-score matching
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 30698554

Group type: EXPERIMENTAL
Intervention: Recognan (citicoline) 500 mg (5 ml) orally for 30 days
Number of subjects: 58

Group type: COMPARATOR
Intervention: Control group (no drug therapy)
Number of subjects: 58
Study: 26690861

Group type: EXPERIMENTAL
Intervention: Electronic Personal Administration of Cognitive Therapy (ePACT)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Small subgroup reinterviewed at Time 3 (n=12)
Number of subjects: 48
Study: 24668203

Group type: EXPERIMENTAL
Intervention: Bilateral extracranial-intracranial direct bypass
Number of subjects: 80

Group type: COMPARATOR
Intervention: Conservative care (nonsurgical)
Number of subjects: 80
Study: 22424000

Group type: EXPERIMENTAL
Intervention: Intravenous glucose, insulin, and potassium (GIK) administered prehospital by paramedics
Number of subjects: 911

Group type: COMPARATOR
Intervention: Placebo administered prehospital by paramedics
Number of subjects: 911
Study: 19950043

Group type: EXPERIMENTAL
Intervention: Acclimatisation protocol (faster ascent)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Acclimatisation protocol (slower ascent)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Altitude increase (up to 6865 m)
Number of subjects: 34

Group type: COMPARATOR
Intervention: No specific intervention
Number of subjects: 34
Study: 17651893

Group type: EXPERIMENTAL
Intervention: fesoterodine 4 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: fesoterodine 8 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: tolterodine ER 4 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 0
Study: 16246772

Group type: EXPERIMENTAL
Intervention: Brimonidine 0.15%
Number of subjects: 80

Group type: COMPARATOR
Intervention: Apraclonidine 0.5%
Number of subjects: 80
Study: 11873008

Group type: EXPERIMENTAL
Intervention: Zidovudine (300 mg), one tablet twice daily from 36-38 weeks' gestation until delivery, then for 7 more days in DITRAME only
Number of subjects: 662

Group type: COMPARATOR
Intervention: Placebo, one tablet twice daily from 36-38 weeks' gestation until delivery, then for 7 more days in DITRAME only
Number of subjects: 662

Group type: EXPERIMENTAL
Intervention: Zidovudine (300 mg) among women with CD4 cell counts < 500/ml
Number of subjects: 662

Group type: COMPARATOR
Intervention: Placebo among women with CD4 cell counts < 500/ml
Number of subjects: 662

Group type: EXPERIMENTAL
Intervention: Zidovudine (300 mg) among women with CD4 cell counts >= 500/ml
Number of subjects: 662

Group type: COMPARATOR
Intervention: Placebo among women with CD4 cell counts >= 500/ml
Number of subjects: 662
Study: 9864079

Group type: EXPERIMENTAL
Intervention: Buspirone (20‐30 mg/day) added to selective serotonin reuptake inhibitors (SSRIs)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Buspirone (20‐30 mg/day) added to clomipramine
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Buspirone augmentation therapy
Number of subjects: 30
Study: 8680900

Group type: EXPERIMENTAL
Intervention: 1.5 g/day mesalazine
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: 3.0 g/day mesalazine
Number of subjects: 169
Study: 2220604

Group type: EXPERIMENTAL
Intervention: Enalapril (daily doses ranged from 2.5 to 40 mg)
Number of subjects: 253

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 253

Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 253
Study: 477676

Group type: EXPERIMENTAL
Intervention: Levamisole (0.5 ml/kg bodyweight b.i.d. for two consecutive days each week for six months)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Placebo (0.5 ml/kg bodyweight b.i.d. for two consecutive days each week for six months)
Number of subjects: 106
Study: 31988253

Group type: EXPERIMENTAL
Intervention: Dynamic exercises on a cycle ergometer combined with CPAP
Number of subjects: 31

Group type: COMPARATOR
Intervention: Breathing exercises and passive mobilization in the sitting position, progressing to active exercises, ambulation, and stair training
Number of subjects: 31
Study: 31079124

Group type: EXPERIMENTAL
Intervention: Various laryngeal grades based on Cormack and Lehane
Number of subjects: 405

Group type: EXPERIMENTAL
Intervention: Age of the patient, opening of mouth, retrognathia, overbite, overjet, limited neck extension, thyromental distance, Mallampati grade, macroglossia
Number of subjects: 405

Group type: EXPERIMENTAL
Intervention: BMI, neck circumference, neck aches, jaw aches, tonsil size, AHI
Number of subjects: 405

Group type: EXPERIMENTAL
Intervention: BMI-adjusted for Asians and Caucasians
Number of subjects: 405
Study: 28183331

Group type: EXPERIMENTAL
Intervention: Dovitinib plus fulvestrant
Number of subjects: 97

Group type: COMPARATOR
Intervention: Placebo plus fulvestrant
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Dovitinib plus fulvestrant (FGF pathway-amplified subgroup)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Placebo plus fulvestrant (FGF pathway-amplified subgroup)
Number of subjects: 97
Study: 25631454

Group type: EXPERIMENTAL
Intervention: Compensatory Cognitive Training (CCT)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 27
Study: 23663288

Group type: EXPERIMENTAL
Intervention: 10-minute VSI in compressions-only CPR
Number of subjects: 488

Group type: EXPERIMENTAL
Intervention: 22-minute VSI in compressions and ventilations
Number of subjects: 488

Group type: COMPARATOR
Intervention: Untrained group
Number of subjects: 488
Study: 21827664

Group type: EXPERIMENTAL
Intervention: Black sesame meal (2.52 g capsules daily for 4 weeks)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo capsules (daily for 4 weeks)
Number of subjects: 30
Study: 19846586

Group type: EXPERIMENTAL
Intervention: Low scores on leadership dimension
Number of subjects: 930

Group type: EXPERIMENTAL
Intervention: Low emotionality
Number of subjects: 930

Group type: EXPERIMENTAL
Intervention: High scores on leadership
Number of subjects: 930

Group type: EXPERIMENTAL
Intervention: Low scores on caring and self‐assertiveness dimensions
Number of subjects: 930
Study: 17298703

Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation (20,000 IU retinol for < 12 months; 45,000 IU retinol for >= 12 months)
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation
Number of subjects: 188

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 188
Study: 14612991

Group type: EXPERIMENTAL
Intervention: Ischemic preconditioning (IP)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 41
Study: 11166780

Group type: EXPERIMENTAL
Intervention: Oxidized low-density lipoproteins (Ox-LDL) levels in patients with CSA
Number of subjects: 37

Group type: COMPARATOR
Intervention: Control group (79 consecutive control patients)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Higher levels of Ox-LDL
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Ox-LDL levels
Number of subjects: 37
Study: 9782219

Group type: COMPARATOR
Intervention: Short-term prophylaxis (subcutaneous UH 15,000 IU/24 h for 15 days)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Long-term prophylaxis (subcutaneous UH 15,000 IU/24 h for 30 days)
Number of subjects: 61
Study: 8167656

Group type: EXPERIMENTAL
Intervention: 8% carbohydrate, low carbonation (8%-C)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 8% carbohydrate, noncarbonated (8%-NC)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Water (0%-NC)
Number of subjects: 8
Study: 3410606

Group type: EXPERIMENTAL
Intervention: 1 mg i.v. methylepoxyproscillaridin (P35)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: 1 mg oral methylepoxyproscillaridin (P35)
Number of subjects: 9
Study: 30630108

Group type: EXPERIMENTAL
Intervention: iAmHealthy intervention (25-contact hour multicomponent intervention delivered over 8 months)
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: iAmHealthy intervention
Number of subjects: 144

Group type: COMPARATOR
Intervention: Monthly newsletter (control)
Number of subjects: 144
Study: 28727701

Group type: EXPERIMENTAL
Intervention: Blinded placebo shockwave treatment
Number of subjects: 106

Group type: COMPARATOR
Intervention: Unblinded placebo shockwave treatment
Number of subjects: 106
Study: 25892151

Group type: EXPERIMENTAL
Intervention: Work-focused intervention (WFI)
Number of subjects: 167

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 167
Study: 23153437

Group type: EXPERIMENTAL
Intervention: PlyD1 at 10 μg
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: PlyD1 at 25 μg
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: PlyD1 at 50 μg
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 22216655

Group type: EXPERIMENTAL
Intervention: Test Dentifrice (0.3% triclosan, 2% PVM/MA copolymer, 0.243% NaF, specially-designed silica)
Number of subjects: 117

Group type: COMPARATOR
Intervention: Positive Control Dentifrice (0.3% triclosan, 2% PVM/MA copolymer, 0.243% NaF in high cleaning silica base)
Number of subjects: 117

Group type: COMPARATOR
Intervention: Negative Control Dentifrice (0.243% NaF in silica base)
Number of subjects: 117
Study: 19906505

Group type: EXPERIMENTAL
Intervention: STEMI patients at admission
Number of subjects: 40

Group type: COMPARATOR
Intervention: NSTEMI patients at admission
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Inflammatory markers (SAA and WBC)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Troponin I
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: WBC and SAA
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: TGF‐beta
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: IL‐6
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Total incidence of major adverse clinical events (MACE)
Number of subjects: 40
Study: 16488376

Group type: EXPERIMENTAL
Intervention: 50 mg glatiramer acetate
Number of subjects: 1651

Group type: EXPERIMENTAL
Intervention: 5 mg glatiramer acetate
Number of subjects: 1651

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1651
Study: 15662998

Group type: EXPERIMENTAL
Intervention: Nigerian citrus honey
Number of subjects: 45